share_log

Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Khan Najat

Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Khan Najat

Recursion Pharmaceuticals | 3：首次持股聲明-董事 Khan Najat
美股sec公告 ·  04/26 05:11
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.
Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.
股票代碼爲RXRX的生物技術公司Recursion Pharmicals, Inc.（Recursion）報告了董事納賈特·汗提交的初步證券實益擁有權聲明。美國證券交易委員會於2024年4月23日提交的表格3表明，汗不以實益方式擁有該公司的任何證券。該表格是1934年《證券交易法》第16（a）條的要求，是在2024年4月16日的一次活動之後提交的。該文件由事實律師喬納森·戈萊特利簽署，證實了汗的董事身份和發行人10％的所有者。該文件是追蹤公司內部人士證券所有權的監管要求的一部分，爲投資者提供了有關公司主要官員持股情況的透明度。
股票代碼爲RXRX的生物技術公司Recursion Pharmicals, Inc.（Recursion）報告了董事納賈特·汗提交的初步證券實益擁有權聲明。美國證券交易委員會於2024年4月23日提交的表格3表明，汗不以實益方式擁有該公司的任何證券。該表格是1934年《證券交易法》第16（a）條的要求，是在2024年4月16日的一次活動之後提交的。該文件由事實律師喬納森·戈萊特利簽署，證實了汗的董事身份和發行人10％的所有者。該文件是追蹤公司內部人士證券所有權的監管要求的一部分，爲投資者提供了有關公司主要官員持股情況的透明度。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。